Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Search
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Rabies prevention local action partnering organizations
Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Global Network | Bioxcellence | Boehringer Ingelheim
Our network of manufacturing facilities spans the globe, from Fremont, in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
expanded-collaboration-MD-Anderson
The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Boehringer Ingelheim and Fraunhofer partnership
Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products
Boehringer Ingelheim Academy Video 2023
Boehringer Ingelheim’s Academy initiative provides networking opportunities, education and facilitates conversations across the innovation community.
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
Zongertinib (BI 1810631)
Zongertinib (BI 1810631)
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
View from Both Sides of the Table
Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
Promising phase II results in chronic kidney disease
Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
Lameness horses collaboration Sleip app artificial intelligence
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
Survodutide Phase III study weight loss
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
world rabies day 2019
world rabies day 2019
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Focus on Alliance Management
Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.